PedAM

Pediatric Disease Annotations & Medicines


	stuttering

Disease ID	1134
Disease	stuttering
Definition	A disturbance in the normal fluency and time patterning of speech that is inappropriate for the individual's age. This disturbance is characterized by frequent repetitions or prolongations of sounds or syllables. Various other types of speech dysfluencies may also be involved including interjections, broken words, audible or silent blocking, circumlocutions, words produced with an excess of physical tension, and monosyllabic whole word repetitions. Stuttering may occur as a developmental condition in childhood or as an acquired disorder which may be associated with BRAIN INFARCTIONS and other BRAIN DISEASES. (From DSM-IV, 1994)
Synonym	dysphemia non-fluent speech stutter stuttered stuttering (finding) stuttering [disease/finding] stuttering nos stutters
DOID	DOID:0060243
UMLS	C0038506
MeSH	D013342
SNOMED-CT	SNOMEDCT_US_2016_09_01:39423001
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:5) C0003467 \| anxiety \| 3 C0026934 \| mycoplasma \| 1 C0038220 \| status epilepticus \| 1 C0004936 \| mental disorders \| 1 C0032302 \| mycoplasma pneumonia \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:1) CNTNAP2 \| 26047 \| CTD_human
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:2) 1813 \| DRD2 \| infer 6531 \| SLC6A3 \| infer
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:89) 2896 \| GRN \| DISEASES 7132 \| TNFRSF1A \| DISEASES 84572 \| GNPTG \| DISEASES 3956 \| LGALS1 \| DISEASES 5816 \| PVALB \| DISEASES 51804 \| SIX4 \| DISEASES 54623 \| PAF1 \| DISEASES 7431 \| VIM \| DISEASES 6783 \| SULT1E1 \| DISEASES 23435 \| TARDBP \| DISEASES 4852 \| NPY \| DISEASES 182 \| JAG1 \| DISEASES 6926 \| TBX3 \| DISEASES 10017 \| BCL2L10 \| DISEASES 23431 \| AP4E1 \| DISEASES 9914 \| ATP2C2 \| DISEASES 25939 \| SAMHD1 \| DISEASES 2033 \| EP300 \| DISEASES 119 \| ADD2 \| DISEASES 793 \| CALB1 \| DISEASES 4240 \| MFGE8 \| DISEASES 6531 \| SLC6A3 \| DISEASES 2904 \| GRIN2B \| DISEASES 23037 \| PDZD2 \| DISEASES 6750 \| SST \| DISEASES 90525 \| SHF \| DISEASES 57465 \| TBC1D24 \| DISEASES 6006 \| RHCE \| DISEASES 152185 \| SPICE1 \| DISEASES 79158 \| GNPTAB \| DISEASES 51181 \| DCXR \| DISEASES 794 \| CALB2 \| DISEASES 171389 \| NLRP6 \| DISEASES 23209 \| MLC1 \| DISEASES 51172 \| NAGPA \| DISEASES 80025 \| PANK2 \| DISEASES 151516 \| ASPRV1 \| DISEASES 1604 \| CD55 \| DISEASES 1272 \| CNTN1 \| DISEASES 1812 \| DRD1 \| DISEASES 83733 \| SLC25A18 \| DISEASES 9021 \| SOCS3 \| DISEASES 255324 \| EPGN \| DISEASES 6900 \| CNTN2 \| DISEASES 885 \| CCK \| DISEASES 57142 \| RTN4 \| DISEASES 1809 \| DPYSL3 \| DISEASES 1739 \| DLG1 \| DISEASES 1798 \| DPAGT1 \| DISEASES 23481 \| PES1 \| DISEASES 8654 \| PDE5A \| DISEASES 26503 \| SLC17A5 \| DISEASES 6752 \| SSTR2 \| DISEASES 1903 \| S1PR3 \| DISEASES 2571 \| GAD1 \| DISEASES 4763 \| NF1 \| DISEASES 51150 \| SDF4 \| DISEASES 58484 \| NLRC4 \| DISEASES 11214 \| AKAP13 \| DISEASES 26047 \| CNTNAP2 \| DISEASES 1813 \| DRD2 \| DISEASES 54964 \| C1orf56 \| DISEASES 8517 \| IKBKG \| DISEASES 6658 \| SOX3 \| DISEASES 11128 \| POLR3A \| DISEASES 8473 \| OGT \| DISEASES 265 \| AMELX \| DISEASES 10171 \| RCL1 \| DISEASES 10675 \| CSPG5 \| DISEASES 56953 \| NT5M \| DISEASES 9244 \| CRLF1 \| DISEASES 1621 \| DBH \| DISEASES 9306 \| SOCS6 \| DISEASES 594857 \| NPS \| DISEASES 3098 \| HK1 \| DISEASES 55041 \| PLEKHB2 \| DISEASES 1052 \| CEBPD \| DISEASES 93986 \| FOXP2 \| DISEASES 57703 \| CWC22 \| DISEASES 9278 \| ZBTB22 \| DISEASES 5424 \| POLD1 \| DISEASES 389333 \| PROB1 \| DISEASES 57451 \| TENM2 \| DISEASES 7033 \| TFF3 \| DISEASES 80790 \| CMIP \| DISEASES 820 \| CAMP \| DISEASES 104355217 \| ERICD \| DISEASES 102723508 \| KANTR \| DISEASES 103752588 \| PACERR \| DISEASES
Locus	(Waiting for update.)

Disease ID	1134
Disease	stuttering
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:8) HP:0000739 \| Anxiety \| 3 HP:0001260 \| Dysarthric speech \| 2 HP:0002167 \| Speech disorder \| 2 HP:0001297 \| Cerebral vascular events \| 1 HP:0000718 \| Aggressive behaviour \| 1 HP:0002133 \| Status epilepticus \| 1 HP:0001250 \| Seizures \| 1 HP:0100033 \| Tic disorder \| 1

Disease ID	1134
Disease	stuttering
Manually Symptom	(Waiting for update.)
Text Mined Symptom	(Waiting for update.)

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:0)
(Waiting for update.)

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:9)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0038506	chlorpromazine	D002746	50-53-3	stuttering	MESH:D013342	marker/mechanism	6110346
C0038506	clozapine	D003024	5786-21-0	stuttering	MESH:D013342	marker/mechanism	11823281
C0038506	fluoxetine	D005473	54910-89-3	stuttering	MESH:D013342	marker/mechanism	11485152
C0038506	gabapentin	C040029	60142-96-3	stuttering	MESH:D013342	marker/mechanism	9054293
C0038506	methylphenidate	D008774	113-45-1	stuttering	MESH:D013342	marker/mechanism	2040720
C0038506	olanzapine	C076029	132539-06-1	stuttering	MESH:D013342	marker/mechanism	15179972
C0038506	theophylline	D013806	58-55-9	stuttering	MESH:D013342	marker/mechanism	7312482
C0038506	valproic acid	D014635	99-66-1	stuttering	MESH:D013342	marker/mechanism	19068016
C0038506	valproic acid	D014635	99-66-1	stuttering	MESH:D013342	therapeutic	11823281

FDA approved drug and dosage information(Total Drugs:14)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D013342	neurontin	gabapentin	100MG	CAPSULE;ORAL	Prescription	AB	Yes	No
MESH:D013342	neurontin	gabapentin	600MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D013342	neurontin	gabapentin	250MG/5ML	SOLUTION;ORAL	Prescription	AA	Yes	Yes
MESH:D013342	neurontin	gabapentin	0	SOLUTION; ORAL	Prescription	None	No	No
MESH:D013342	neurontin	gabapentin	600MG	TABLET; ORAL	Prescription	None	No	No
MESH:D013342	neurontin	gabapentin	800MG	CAPSULE; ORAL	Prescription	None	No	No
MESH:D013342	neurontin	gabapentin	250MG/5ML	SOLUTION; ORAL	Prescription	None	No	No
MESH:D013342	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
MESH:D013342	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
MESH:D013342	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
MESH:D013342	zyprexa	olanzapine	2.5MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D013342	zyprexa	olanzapine	10MG/VIAL	INJECTABLE;INTRAMUSCULAR	Prescription	AP	Yes	Yes
MESH:D013342	zyprexa	olanzapine	2.5MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D013342	zyprexa	olanzapine	10MG/VIAL	INJECTABLE;INTRAMUSCULAR	Prescription	AP	Yes	Yes

FDA labeling changes(Total Drugs:14)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D013342	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D013342	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D013342	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D013342	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D013342	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D013342	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D013342	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D013342	6/4/2006	daytrana	methylphenidate	ADHD	Summary is pending	Labeling	-	P	-	-	Shire	-	FALSE'
MESH:D013342	12/14/2009	daytrana	methylphenidate	Postmarketing safety study	Information added to Warnings and Adverse Reactions on skin reactions observed in a postmarketing dermal study in pediatric patients	Labeling	-	P	-	-	Shire	-	FALSE'
MESH:D013342	06/29/2010	daytrana	methylphenidate	ADHD	Expanded pediatric indication to include adolescent patients ages13-17 years The most commonly reported adverse reactions in a trial in patients 13-17 years included appetite decreased, nausea, insomnia, weight decreased, dizziness, abdominal pain, and anorexia. The majority of patients had erythema at the application site Information on PK parameters, Adverse Event profile and clinical studies	Labeling	-	P	-	-	Shire	-	FALSE'
MESH:D013342	08/14/2008	zyprexa	olanzapine	schizophrenia; bipolar disorder	Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg	-	B	-	-	-	Lilly	10/1/2007	FALSE'
MESH:D013342	08/14/2008	zyprexa	olanzapine	schizophrenia; bipolar disorder	Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg	-	B	-	-	-	Lilly	10/1/2007	FALSE'
MESH:D013342	4/12/2009	zyprexa	olanzapine	Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17	Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies	Labeling	B	-	-	-	Lilly	10/1/2007	TRUE'
MESH:D013342	4/12/2009	zyprexa	olanzapine	Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17	Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies	Labeling	B	-	-	-	Lilly	10/1/2007	TRUE'

Web
Analytics